99% Savings - Buy Just @1 Rs X
Cefpra S 500 Mg/250 Mg Injection, a prescription drug, is manufactured in various forms such as Injection. Cefpra S 500 Mg/250 Mg Injection also has some secondary and off-label uses. These are listed below.
The optimal dosage of Cefpra S 500 Mg/250 Mg Injection is largely dependent on the individual's body weight, medical history, gender and age. The condition it has been prescribed for, and the route of administration also determine the right dosage. Refer to the dosage section for a detailed discussion.
Cefpra S 500 Mg/250 Mg Injection also has some side effects, the most common being Diarrhoea, Rash, Allergic reaction. Apart from the aforementioned side effects, Cefpra S 500 Mg/250 Mg Injection can also lead to other problems, which have been listed below. Usually, these side effects of Cefpra S 500 Mg/250 Mg Injection go away soon, and do not persist beyond the duration of the treatment. If, however, they worsen or do not go away, please speak with your physician.
In addition, Cefpra S 500 Mg/250 Mg Injection's effect is Safe during pregnancy and Mild for lactating mothers. In addition, Cefpra S 500 Mg/250 Mg Injection's effects on the liver, heart and kidney are discussed below in the Cefpra S 500 Mg/250 Mg Injection related warnings section.
Cefpra S 500 Mg/250 Mg Injection is not recommended if you suffer from certain medical conditions as it can have adverse effects. Allergy are examples of such conditions.
Drug interactions for Cefpra S 500 Mg/250 Mg Injection have been reported in the medical literature. Refer to the list below for further details.
In addition to these precautions, you may also note that Cefpra S 500 Mg/250 Mg Injection is not safe while driving, and is is not addictive in nature.
Cefpra S 500 Mg/250 Mg Injection is used to treat the following -
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
13 - 18 years (Adolescent) |
|
Adult |
|
Geriatric |
|
Is the use of Cefpra S 500 Mg/250 Mg Injection safe for pregnant women?
Pregnant women can take Cefpra S without worrying about any side effects.
Is the use of Cefpra S 500 Mg/250 Mg Injection safe during breastfeeding?
Side effects of Cefpra S on breastfeeding women are very mild.
What is the effect of Cefpra S 500 Mg/250 Mg Injection on the Kidneys?
Information about safety of Cefpra S for kidney is not available since scientific research on this topic is yet to be done.
What is the effect of Cefpra S 500 Mg/250 Mg Injection on the Liver?
Cefpra S may cause harmful effects on liver. if you feel it's having any such effect, then stop taking this drug, and restart only on your doctor's advice.
What is the effect of Cefpra S 500 Mg/250 Mg Injection on the Heart?
In the absence of any scientific study on the side effects of Cefpra S on the heart, information on safety of Cefpra S for the heart is unavailable.
If you are suffering from any of the following diseases, you should not take Cefpra S 500 Mg/250 Mg Injection unless your doctor advises you to do so -
Is this Cefpra S 500 Mg/250 Mg Injection habit forming or addictive?
No, there is no any evidence that Cefpra S 500 Mg/250 Mg Injection is addictive.
Is it safe to drive or operate heavy machinery when consuming?
After taking Cefpra S 500 Mg/250 Mg Injection you may feel sleepy. So it is not advised to perform these activities.
Is it safe?
Yes, but consume Cefpra S 500 Mg/250 Mg Injection only on doctor's advice.
Is it able to treat mental disorders?
Cefpra S 500 Mg/250 Mg Injection is unable to treat or cure mental disorders.
Interaction between Food and Cefpra S 500 Mg/250 Mg Injection
You can take Cefpra S 500 Mg/250 Mg Injection with food.
Interaction between Alcohol and Cefpra S 500 Mg/250 Mg Injection
Information about the interaction of Cefpra S 500 Mg/250 Mg Injection and alcohol is not currently available because this topic has not been researched yet.
Cefpra S is a brand name for ceftriaxone. It is a prescription drug that belongs to the class of medication called cephalosporins. It is a broad spectrum antibiotic, used for treating bacterial infections, such as bronchitis, gonorrhea, respiratory, ear, throat, and urinary tract infection.
Avoid taking Cefpra S with azithromycin, because it can cause heart-related problems. However, if you are experiencing any discomfort after consuming these two medicines at the same time then do not hesitate to inform your doctor.
Occasionally Cefpra S can cause drug-induced thrombocytopenia (blood clot formation in a vessel). However, if you experience severe thrombocytopenia after taking this medicine, please immediately seek medical help.
Cefpra S and doxycycline can be taken together, as there are no reported harmful interactions between them. However, it doesn't mean that no interactions exist between them. Please take if prescribed by a doctor.
Yes, Cefpra S can cause liver toxicity if taken in higher doses for a long time. You are advised to get regular liver function tests done to keep a check on proper liver functioning while taking this drug.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Ceftriaxone
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 727-728
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 307-311
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; UNASYN® (ampicillin sodium/sulbactam sodium)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 725
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 160-162